MULTIPLE MYELOMA RESEARCH FOUNDATION
DONOR PROGRESS REPORT 2011

POWERFUL THINKING ADVANCES THE CURE®
Dear Friends,

2011 was, by any measure, a game changing year for the Multiple Myeloma Research Foundation (MMRF) and Multiple Myeloma Research Consortium (MMRC). Significant philanthropic gifts from our major donors and strong support from our expansive donor base allowed us to make a record-breaking investment in a cutting-edge portfolio of research programs that will rapidly accelerate the development of effective new treatments for multiple myeloma and propel us closer to a cure.

In 2011, we broke new ground with our most ambitious model to date: the Multiple Myeloma Personalized Medicine Initiative, a breakthrough program that will radically transform the discovery and development of individualized treatments for the disease. At that heart of the Initiative is the MMRF CoMMpassSM (Relating Clinical Outcomes in MM to Personal Assessment of Genetic Profile) study, a highly collaborative study that aims to greatly deepen our understanding of multiple myeloma at its most basic level as the first step in developing individualized cancer treatments. Like our flagship Multiple Myeloma Genomics Initiative, CoMMpass demanded the vision and leadership of a trusted third party like us to design, execute, and achieve what no single institution could alone.

2011 was also a banner year for the MMRC, which spearheaded the launch of eight clinical trials of new and combination therapies – more than any year to date. These treatments are so promising that two – carfilzomib and pomalidomide – are expected to become next FDA-approved treatments for myeloma and others are advancing rapidly to the next phase of development where they will be widely available to patients.

Key to all of this progress were the incredible partnerships we have forged over the past years with industry and academia alike. In 2011, we built an even stronger global network with the funding of 24 Senior Research Awards, Research Fellow Grants and special Requests for Applications in the United States, Canada, Australia and the Netherlands.

In 2011, we continued our outstanding record of accountability, earning Charity Navigator’s highly coveted four-star rating for the ninth consecutive year – a distinction only one percent of all non-profits have achieved. Notably, we did so in one of the most challenging global economies in recent history – surpassing our peers in fiscal responsibility and proving that our business approach to science works.

With these results fueling our momentum, we are poised to make 2012 the best year yet for multiple myeloma patients and their loved ones. Thank you, as always, for your vital support.

Sincerely,

Kathy Giusti
Founder and CEO
Multiple Myeloma Research Foundation

Walter M. Capone
Chief Operating Officer
Multiple Myeloma Research Foundation
We maximize the most of every dollar raised by investing in programs we believe will have the greatest patient-impact. In 2011, we:

- Funded **12 Senior Research Awards**, **12 Research Fellows Awards** and **one Biotech Investment Award** to support innovative research into the discovery and development of the next treatment breakthroughs.

- Launched the MMRF CoMMpass™ study, the cornerstone of the Multiple Myeloma Personalized Medicine Initiative. CoMMpass, builds on knowledge gained from the Multiple Myeloma Genomics Initiative (MMGI) that demonstrated multiple myeloma’s extreme genetic diversity and the need to deeply understand this complex disease to develop new treatments that offer the promise of extended remissions.

Like the MMGI, CoMMpass is a highly collaborative model that aims to achieve what no single center could execute alone—molecular profiling of at least 1,000 patients from first diagnosis and subsequently through the course of their disease. Using an unprecedented suite of genomics platforms, CoMMpass data will represent the most comprehensive and sophisticated view of multiple myeloma ever seen and will help us generate hypotheses as to how to classify patients and tailor treatments according to their molecular profile.

Similar to the MMGI, CoMMpass has circumvented data ownership and IP concerns, critical issues that often stalemate research collaborations, by ensuring that all clinical and genomic data generated by CoMMpass is put into a free, web-based portal.

**HIGHLIGHTS**

"The rigor and breadth of this effort will enable a much more sophisticated understanding of the molecular changes that give rise to myeloma, and that affect a patient's course of disease. We believe the collective data to emerge along the way will provide an invaluable resource for innovators to design the next significant breakthroughs against this incurable disease."

---

"John Carpten, Ph.D.,
Professor and Director of Integrated Cancer Genomics Division, TGen"
HIGHLIGHTS

• Opened a record-breaking **eight new clinical trials** through the MMRC in top speed, bringing the total number of compounds studied through our clinical network to 38.

• Launched **C-MAP**, the first early drug access program in multiple myeloma to be offered by a foundation. This important program has become a lifeline for hundreds of patients with no remaining treatments options, allowing them to access carfilzomib.

• Received our **ninth consecutive 4-star rating** – the highest rating possible – from Charity Navigator, the nation’s premier independent evaluator of charitable organizations. Charity Navigator’s 4-star rating is awarded only to nonprofits that exceed industry standards and regularly outperform other charities, a distinction only one percent of non-profits have received.

• Earned incredible validation of our model, most notably our Founder and CEO, Kathy Giusti, being named one of **TIME Magazine’s 100 Most Influential People in the World**. Giusti was also selected to deliver Harvard Business School’s Class Day address, featured in the book *The Humanitarian Leader in All of Us*, and a Harvard Business Review feature article.

> “We share the MMRF’s vision that to succeed we will not only need great science, but also the creation of innovative models for collaboration to accelerate rapid development of promising treatments.”

– N. Anthony Coles, M.D.,
President and CEO, Onyx

> “Cancer has touched someone in all of our lives. It is my hope that, by continuing to raise awareness and research funds we can play a role in helping the MMRF bring patients new treatments that will extend their lives.”

– Stevie Wonder,
Spirit of Hope Award Honoree
2011 MMRF Fall Gala
FINANCIAL SUMMARY

MMRF 2011 Source of Funds*

- 28% Events
- 33% Healthcare Corporations
- 27% Private Foundations
- 8% Individuals
- 4% Other

*Based on gross revenue

MMRF 2011 Spending Allocations

- 90.4% Research Awards and Programs*
- 7.4% Fundraising
- 2.2% Administrative Costs

*Research Awards and Programs

- 44.2% Clinical Research
- 12.6% Translational Research
- 15.4% Education
- 15.7% Basic Science
- 12.1% Program Support

*Based on gross revenue
### MULTIPLE MYELOMA RESEARCH FOUNDATION, INC

**Statements of Activities (Audited) – Years Ended December 31, 2011 and December 31, 2010**

<table>
<thead>
<tr>
<th>Support and revenue</th>
<th>2011</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>$10,681,787</td>
<td>$8,188,625</td>
</tr>
<tr>
<td>Private foundation grants</td>
<td>7,795,430</td>
<td>10,215,460</td>
</tr>
<tr>
<td>Fee for service</td>
<td>1,426,530</td>
<td>—</td>
</tr>
<tr>
<td>Federal grant support</td>
<td>330,345</td>
<td>392,759</td>
</tr>
<tr>
<td>In-kind contribution</td>
<td>214,324</td>
<td>64,054</td>
</tr>
<tr>
<td><strong>Total support and revenue</strong></td>
<td><strong>26,531,964</strong></td>
<td><strong>24,329,799</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Expenses</th>
<th>2011</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research</td>
<td>16,516,780</td>
<td>13,757,372</td>
</tr>
<tr>
<td>Education</td>
<td>2,753,263</td>
<td>2,178,774</td>
</tr>
<tr>
<td>Awareness</td>
<td>757,249</td>
<td>407,546</td>
</tr>
<tr>
<td>Other program expenses</td>
<td>2,743,483</td>
<td>1,750,771</td>
</tr>
<tr>
<td><strong>Total program expenses</strong></td>
<td><strong>22,770,775</strong></td>
<td><strong>18,094,463</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Supporting services</th>
<th>2011</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Management and general</td>
<td>551,236</td>
<td>566,445</td>
</tr>
<tr>
<td>Fundraising</td>
<td>1,864,404</td>
<td>1,544,172</td>
</tr>
<tr>
<td><strong>Total supporting services</strong></td>
<td><strong>2,415,640</strong></td>
<td><strong>2,110,617</strong></td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td><strong>25,186,415</strong></td>
<td><strong>20,205,080</strong></td>
</tr>
</tbody>
</table>

| Change in net assets | 1,345,549     | 4,124,719     |
| Net assets, beginning of year | 13,211,617 | 9,086,898 |
| Net assets, end of year | **$14,557,166** | **$13,211,617** |
LEADERSHIP COUNCIL
Joseph M. Hogan
Lester B. Knight
Philip J. Purcell
William Wilson III
Robert Wolf

BOARD OF DIRECTORS
W. Dana LaForge, Chairman
Kenneth C. Anderson, M.D.
Karen Andrews
William K. Bowes, Jr.
Frank Douglas, M.D., Ph.D.
Kathy Giusti
Stephen Grand
Eugene Grisanti
Alan L. Heller
Anthony K. Kesman
Lori Marcus
Gerald McDougall
William S. McKiernan
Chris A. McWilton
Mike Mortimer
Charles B. Ortner
David R. Parkinson, M.D.
Marie Pinizzotto, M.D.
Michael Reinert
Donna Zaccaro Ullman
Pat Williams
Meryl Zausner

HONORARY BOARD
Lance Armstrong
Dusty Baker
Tiki Barber
Don Baylor
James T. Brown
Diahann Carroll
Bob Costas
Katie Couric
Cindy Crawford
Ann Curry
Scott Hamilton
Mariska Hargitay
Lou Holtz
Bonnie Hunt
Senator Kay Bailey Hutchison
Dan Jansen
Hoda Kotb
Diana Krall
Eric McCormack
Deborah Norville
Sharon Osbourne
Carl Quintanilla
Al Roker
General Norman Schwarzkopf
Mel Stottlemyre
Brian Williams
Bob Woodruff
Lee Woodruff

TECHNOLOGY BOARD
Kenneth C. Anderson, M.D., Ph.D., Chairman
Bart Barlogie, M.D., Ph.D.
Richard Caprioli, Ph.D.
Arul Chinnaiyan, M.D., Ph.D.
William Dalton, Ph.D., M.D.
Nicholas Dracopoli, Ph.D.
Ellen Feigal, M.D.
Daniel Von Hoff, M.D.
Carl June, M.D.
David R. Parkinson, M.D.
G. David Roodman, M.D., Ph.D.
Louis M. Staudt, M.D., Ph.D.
Freda K. Stevenson, M.Sc., D.Phil., F.R.C.P.
Richard Wahl, M.D.